Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
Germany-based Biofrontera has entered into an agreement to acquire all shares in Cutanea Life Sciences through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co Japan as the seller. 26 March 2019
Biotechnology
The US Food and Drug Administration has approved another indication for Dupixent (dupilumab), this time for adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 12 March 2019
Biotechnology
Ilumetri (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody from Spanish drugmaker Almirall, has been recommended by the National Institute for Health and Care Excellence (NICE) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. 11 March 2019
Biotechnology
New Ilumya (tildrakizumab-asmn) clinical insights were presented over the weekend at the 2019 American Academy of Dermatology (AAD) Annual Meeting, including long-term data showing sustained skin clearance in some patients living with moderate-to-severe plaque psoriasis after three years of ongoing treatment with Ilumya. 4 March 2019
Pharmaceutical
At its last meeting in London before moving to new headquarters in Amsterdam as a result of Brexit, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) made positive recommendations for the approval of seven novel medicines. 1 March 2019
Pharmaceutical
Shares in Spanish dermatology specialist Almirall closed 4% up on Monday after the company announced its financial results for 2018. 25 February 2019
Biotechnology
Regeneron Pharmaceuticals has announced two important legal developments invalidating Immunex patents with functional claims to antibodies that target human interleukin-4 receptors (IL-4R). 18 February 2019
Biotechnology
Spanish dermatology specialist Almirall has agreed to buy an option from California’s Dermira related to the investigational biologic lebrikizumab. 12 February 2019
Biotechnology
A new company with 7.8 million Swiss francs ($7.8 million) in funding has been created to take forward an asset from private biopharma Aurealis Pharma. 11 February 2019
Pharmaceutical
Among last week’s news, GlaxoSmithKline’s up to $4.23 billion immuno-oncology deal with Merck KGaA is a clear indication of the UK pharma major’s return to the cancer arena. Also on the deal-making front, Alexion Pharma entered into a collaboration with Caelum Bioscience for CAEL-101, a potential treatment for the rare disease light chain amyloidosis. Regulatory news attracting attention included US Food and Drug Administration approval for Sanofi’s rare disease drug Cablivi, and Evolus gaining FDA clearance for its Jeuveau, a rival to Allergan’s blockbuster aesthetics Botox brand. 10 February 2019
Pharmaceutical
Appaloosa, the US hedge fund managed by billionaire David Tepper, has called for major and immediate change at Allergan, the Ireland-based drugmaker that is best known for its Botox (onabotulinumtoxinA) product. 6 February 2019
Biotechnology
Baricitinib has met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase III studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis (AD). 4 February 2019
Pharmaceutical
The US Food and Drug Administration has approved Evolus’ lead product, Jeuveau (prabotulinumtoxinA-xvfs), for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines associated with corrugator and/or procerus muscle activity in adults. 4 February 2019
Pharmaceutical
Shares in Dublin-headquartered drugmaker Allergan have fallen sharply amid concerns over lower-than-expected revenues and impending competition. 30 January 2019
Biotechnology
Results from a pooled analysis of four Phase III clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline. 28 January 2019
Biotechnology
The Australian government said on Friday that it will make two new medicines for the treatment of the skin condition psoriasis more affordable, saving patients up to A$32,600 ($23.453) per year. 28 January 2019
Biotechnology
Pharma’s increasing ability to address unmet need in plaque psoriasis with a range of different approaches is helping the market to rise at a compound annual growth rate (CAGR) of 4.1%. 23 January 2019
Pharmaceutical
Patients in England who have a mutation of the most serious and life-threatening type of skin cancer will now have a new treatment option. 21 January 2019
Pharmaceutical
Swiss pharma giant Novartis (NOVN: VX) is to work with the University of Oxford’s Big Data Institute (BDI) to improve drug research and development using artificial intelligence (AI). 18 January 2019
Pharmaceutical
Almirall's affiliate in the USA has announces the launch of Seysara (sarecycline), a novel tetracycline-derived oral antibiotic and the first to be developed specifically for the treatment of acne. 18 January 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze